CCNE1 and lung cancer: Overexpression of cyclin E1 has been recognized in various malignancies including lung cancer (51%–62%), breast cancer (53%–61%), liver cancer (36%–68%) and some sarcomas (29%–61%) (15, 17, 22–28).